IMRN
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Ref P/E N/A, P/B 0.70
- P/B ratio of 0.70 suggests asset undervaluation
- Negative earnings make P/E and PEG ratios irrelevant
- No Graham Number available due to lack of earnings
Ref Growth rates
- Slight positive revenue growth (4.8%)
- Revenue growth is negligible for a biotech firm
- Forward P/E is deeply negative (-79.30)
Ref Historical trends
- 5Y Change of -85.9%
- Consistent downward trajectory across all timeframes
Ref Piotroski F-Score
- Extremely low debt
- High current ratio
- Piotroski F-Score of 3/9 indicates poor operational health
Ref Yield, Payout
- No dividend history
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for IMRN and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
IMRN
Immuron Limited
Primary
|
-85.9% | -59.6% | -51.9% | -61.7% | -3.3% | -1.0% |
|
GELS
Gelteq Limited
Peer
|
-73.9% | -73.9% | -14.8% | -43.5% | +3.7% | +13.2% |
|
EVGN
Evogene Ltd.
Peer
|
-98.3% | -86.8% | -23.5% | -45.0% | +5.7% | -0.8% |
|
ALUR
Allurion Technologies Inc.
Peer
|
-99.8% | -99.8% | -84.6% | -75.5% | -69.7% | -11.7% |
|
BMRA
Biomerica, Inc.
Peer
|
-95.7% | -88.5% | -46.5% | -34.3% | -3.0% | 0.0% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
IMRN
Immuron Limited
|
BEARISH | $8.1M | - | -39.7% | -62.1% | $0.79 | |
|
GELS
Gelteq Limited
|
BEARISH | $8.23M | - | -43.0% | -% | $0.77 | Compare |
|
EVGN
Evogene Ltd.
|
BEARISH | $7.95M | - | -100.7% | -220.2% | $0.8 | Compare |
|
ALUR
Allurion Technologies Inc.
|
BEARISH | $7.92M | - | -% | -187.9% | $0.53 | Compare |
|
BMRA
Biomerica, Inc.
|
BEARISH | $7.76M | - | -84.3% | -90.3% | $2.57 | Compare |
Past News Coverage
Recent headlines mentioning IMRN from our newsroom.